BIOMAT Database Logo BIOMAT Database Logo

Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon. 2003

Maurizia Rossana Brunetto, and Filippo Oliveri, and Piero Colombatto, and Barbara Coco, and Pietro Ciccorossi, and Ferruccio Bonino
U.O. Gastroenterologia ed Epatologia, Azienda Ospedaliera, Universitaria Pisana, Pisa, Italy. brunetto@med-club.com

UI MeSH Term Description Entries
D007372 Interferons Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions. Interferon
D011092 Polyethylene Glycols Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS. Macrogols,Polyoxyethylenes,Carbowax,Macrogol,Polyethylene Glycol,Polyethylene Oxide,Polyethyleneoxide,Polyglycol,Glycol, Polyethylene,Glycols, Polyethylene,Oxide, Polyethylene,Oxides, Polyethylene,Polyethylene Oxides,Polyethyleneoxides,Polyglycols,Polyoxyethylene
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006513 Hepatitis B e Antigens A closely related group of antigens found in the plasma only during the infective phase of hepatitis B or in virulent chronic hepatitis B, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins G. HBeAg,Hepatitis B e Antigen,Hepatitis Be Antigen,e Antigen,e Antigens,HBe Ag-1,HBe Ag-2,Hepatitis Be Antigens,Antigen, Hepatitis Be,Antigen, e,Antigens, Hepatitis Be,Antigens, e,Be Antigen, Hepatitis,Be Antigens, Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Maurizia Rossana Brunetto, and Filippo Oliveri, and Piero Colombatto, and Barbara Coco, and Pietro Ciccorossi, and Ferruccio Bonino
Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon.
January 2011, Liver international : official journal of the International Association for the Study of the Liver,
Maurizia Rossana Brunetto, and Filippo Oliveri, and Piero Colombatto, and Barbara Coco, and Pietro Ciccorossi, and Ferruccio Bonino
Predictors of response to pegylated interferon treatment in HBeAg-negative patients with chronic hepatitis B.
December 2014, Journal of infection in developing countries,
Maurizia Rossana Brunetto, and Filippo Oliveri, and Piero Colombatto, and Barbara Coco, and Pietro Ciccorossi, and Ferruccio Bonino
Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
February 2013, Liver international : official journal of the International Association for the Study of the Liver,
Maurizia Rossana Brunetto, and Filippo Oliveri, and Piero Colombatto, and Barbara Coco, and Pietro Ciccorossi, and Ferruccio Bonino
HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?
February 2014, Liver international : official journal of the International Association for the Study of the Liver,
Maurizia Rossana Brunetto, and Filippo Oliveri, and Piero Colombatto, and Barbara Coco, and Pietro Ciccorossi, and Ferruccio Bonino
Efficacy of PEGylated Interferon in Treatment-Experienced Chinese Patients With HBeAg Positive Chronic Hepatitis B.
April 2016, Hepatitis monthly,
Maurizia Rossana Brunetto, and Filippo Oliveri, and Piero Colombatto, and Barbara Coco, and Pietro Ciccorossi, and Ferruccio Bonino
Interferon treatment with or without oral ganciclovir in HBeAg-negative chronic hepatitis B: a randomized study.
May 2000, Journal of viral hepatitis,
Maurizia Rossana Brunetto, and Filippo Oliveri, and Piero Colombatto, and Barbara Coco, and Pietro Ciccorossi, and Ferruccio Bonino
A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative.
July 2005, Hepatology (Baltimore, Md.),
Maurizia Rossana Brunetto, and Filippo Oliveri, and Piero Colombatto, and Barbara Coco, and Pietro Ciccorossi, and Ferruccio Bonino
Treatment of HBeAg-negative chronic hepatitis B.
February 2003, Seminars in liver disease,
Maurizia Rossana Brunetto, and Filippo Oliveri, and Piero Colombatto, and Barbara Coco, and Pietro Ciccorossi, and Ferruccio Bonino
Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B.
January 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Maurizia Rossana Brunetto, and Filippo Oliveri, and Piero Colombatto, and Barbara Coco, and Pietro Ciccorossi, and Ferruccio Bonino
Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.
February 2013, Liver international : official journal of the International Association for the Study of the Liver,
Copied contents to your clipboard!